Accessible cartilage tumor malignancy prediction via vision-language foundation model adaptation.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 41547682.
- Also identified by DOI 10.1007/s00256-026-05131-4.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To predict cartilage tumor malignancy from radiographic images combined with readily available non-imaging information based on a vision-language foundation model. This single-institution study assembled a dataset of 3336 radiographs from 455 patients with enchondroma or chondrosarcoma that was assembled from two sources: (1) patients with histopathology-confirmed diagnoses of enchondroma or chondrosarcoma, and (2) patients with imaging-stable enchondroma without biopsy, confirmed through long-term imaging follow-up. An adapted vision-language foundation model based on the pre-trained CLIP (Contrastive Language-Image Pretraining) architecture was fine-tuned with our proposed Medical Knowledge Adapters and evaluated using 10-fold patient-level cross-validation to predict cartilage tumor malignancy from plain radiographs and demographic information. Using radiographs alone, the model achieved an Areas Under the receiver operating characteristic Curve (AUC) of 0.91 ± 0.04. Incorporating demographics improved the AUC to 0.94 ± 0.02. Subgroup analysis demonstrated robust generalizability across tumor grades with an AUC of 0.91 ± 0.07 in distinguishing atypical cartilaginous tumors (ACT) previously known as low grade chondrosarcomas, and 0.95 ± 0.02 in differentiating high-grade chondrosarcomas from enchondromas. Within the clinically challenging extremity subgroup (enchondroma vs ACT/LGCS), the model achieved an AUC of 0.79 ± 0.14, reflecting diagnostic difficulty observed in clinical practice. This foundation model-based approach demonstrates strong performance using accessible data sources, offering a non-invasive, cost-efficient, and scalable solution for cartilage tumor assessment in musculoskeletal oncology.